Filter Results
:
(61)
Show Results For
-
All HBS Web
(237)
- Faculty Publications (61)
Show Results For
-
All HBS Web
(237)
- Faculty Publications (61)
- March 2016
- Case
Evive Health and Workplace Influenza Vaccinations
By: John Beshears
Evive Health is a company that manages communication campaigns on behalf of health insurance plans and large employers. Using big data techniques and insights from behavioral economics, Evive deploys targeted and effective messages that improve individuals' health...
View Details
Keywords:
Vaccination;
Influenza;
Flu Shot;
Preventive Care;
Health Care;
Behavioral Economics;
Choice Architecture;
Nudge;
Experimental Design;
Randomized Controlled Trial;
RCT;
Causal Inference;
Consumer Behavior;
Health Care and Treatment;
Health Testing and Trials;
Communication Strategy;
Health Industry
Beshears, John. "Evive Health and Workplace Influenza Vaccinations." Harvard Business School Case 916-044, March 2016.
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire...
View Details
Keywords:
CV Ingenuity;
CVI;
Drug Eluting Balloon;
DEB;
Drug Eluting Stent;
Angioplasty Balloon;
FoxHollow;
Medical Device;
Medical Device Startup;
Premarket Approval;
PMA;
Lutonix;
Stellarex;
LEVANT;
ILLUMENATE;
Clinical Trials;
Peripheral Arterial Disease;
PAD;
Healthcare Startups;
Covidien;
Health Care and Treatment;
Health Testing and Trials;
Business Startups;
Commercialization;
Health Industry;
Medical Devices and Supplies Industry;
United States;
Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies." Harvard Business School Case 315-045, March 2015. (Revised January 2024.)
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The...
View Details
Keywords:
CV Ingenuity;
CVI;
Drug Eluting Balloon;
DEB;
Drug Eluting Stent;
Angioplasty Balloon;
FoxHollow;
Medical Device;
Medical Device Startup;
Premarket Approval;
PMA;
Lutonix;
Stellarex;
LEVANT;
ILLUMENATE;
Clinical Trials;
Peripheral Arterial Disease;
PAD;
Healthcare Startups;
Covidien;
Health Care and Treatment;
Health Testing and Trials;
Business Startups;
Commercialization;
Strategy;
Health Industry;
Medical Devices and Supplies Industry;
United States;
Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (B): Epilogue." Harvard Business School Supplement 315-087, March 2015. (Revised February 2022.)
- March 2015
- Case
Twine Health
By: Robert S. Huckman, Ariel D. Stern and Matthew G. Preble
In late 2014, Dr. John Moore (CEO), Frank Moss (chairman), and Scott Gilroy (CTO) of Twine Health (Twine) had to resolve several challenges that threatened to restrict the widespread dissemination of its sole product, Twine. Twine was a cloud-based platform that...
View Details
Keywords:
Health Care;
Chronic Disease;
Technology Adoption;
Digital Health;
Health Acceleration Challenge;
Strategy;
Disease Management;
Health;
Health Care and Treatment;
Information Technology;
Mobile and Wireless Technology;
Health Industry;
United States;
Massachusetts
Huckman, Robert S., Ariel D. Stern, and Matthew G. Preble. "Twine Health." Harvard Business School Case 615-068, March 2015.
- June 2014 (Revised February 2017)
- Case
Kathy Giusti and the Multiple Myeloma Research Foundation
By: Richard G. Hamermesh, Joshua D. Margolis and Matthew G. Preble
What do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its...
View Details
Keywords:
Philanthropy;
Philanthropy Funding;
Entrepreneurship;
Health Care;
Management Styles;
Personalized Medicine;
Health Care Outcomes;
Cancer;
Cancer Care In The U.S.;
Personal Care;
Leadership;
Leading Change;
Social Entrepreneurship;
Philanthropy and Charitable Giving;
Health Care and Treatment;
Leadership Style;
Management Style;
Management Skills;
Growth and Development Strategy;
Business Strategy;
Health;
Health Industry;
United States;
Canada;
Spain
Hamermesh, Richard G., Joshua D. Margolis, and Matthew G. Preble. "Kathy Giusti and the Multiple Myeloma Research Foundation." Harvard Business School Case 814-026, June 2014. (Revised February 2017.)
- October 2013
- Case
FasterCures: Removing Barriers to Treatments
By: Richard G. Hamermesh and James Weber
In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit... View Details
Keywords:
Health Care;
Health Care Industry;
Health Care Policy;
Health Services;
Healthcare;
Healthcare Reform;
Healthcare Ventures;
Nonprofit;
Non-profit Management;
Not-for-profit;
Incubator;
Accelerator;
Venture Philanthropy;
Medical Services;
Medical Solutions;
Medical Research;
Medical Treatment;
Clinical Trials;
Drug Reimbursement;
Early Stage;
Early Stage Research Funding;
Early Stage Funding;
Milken Institute;
Michael Milken;
David Baltimore;
Partnering For Cures;
National Institutes Of Health;
Cancer Care In The U.S.;
Cancer Care Services;
Policy-making;
Health Care and Treatment;
Health;
Health Testing and Trials;
Entrepreneurship;
Social Entrepreneurship;
Nonprofit Organizations;
Policy;
Health Industry;
United States;
District of Columbia
Hamermesh, Richard G., and James Weber. "FasterCures: Removing Barriers to Treatments." Harvard Business School Case 814-003, October 2013.
- September 2012 (Revised November 2014)
- Case
Cialis Lifecycle Management: Lilly's BPH Dilemma
By: Elie Ofek and Natalie Kindred
How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new...
View Details
Keywords:
Product Positioning;
Attitudes;
Brands and Branding;
Pharmaceutical Industry;
United States
Ofek, Elie, and Natalie Kindred. "Cialis Lifecycle Management: Lilly's BPH Dilemma." Harvard Business School Case 513-005, September 2012. (Revised November 2014.)
- July 2011 (Revised September 2012)
- Case
Intraoperative Radiotherapy for Breast Cancer (A)
By: Willy Shih
"This trial is going to take longer." Those were words that Michael Kaschke, CEO of Carl Zeiss AG, was not surprised to hear as he nurtured the intraoperative radiotherapy business inside his company's microsurgery unit. But he also didn't expect it to take 13 years to...
View Details
Keywords:
Finance;
Business History;
Disruptive Innovation;
Emerging Markets;
Organizational Change and Adaptation;
Research and Development;
Safety
Shih, Willy. "Intraoperative Radiotherapy for Breast Cancer (A)." Harvard Business School Case 612-003, July 2011. (Revised September 2012.)
- November 2009 (Revised August 2010)
- Case
NovoCure Ltd.
By: William A. Sahlman and Sarah Flaherty
Venture capitalist William Doyle must raise $35 million for a portfolio company with a promising, novel cancer therapy, just as global capital markets are imploding in the fall of 2008. NovoCure, Ltd., has developed an electrical-field-based therapy, called Tumor...
View Details
Keywords:
Financial Crisis;
Entrepreneurship;
Venture Capital;
Investment;
Health Care and Treatment;
Health Testing and Trials;
Technological Innovation;
Financial Services Industry
Sahlman, William A., and Sarah Flaherty. "NovoCure Ltd." Harvard Business School Case 810-045, November 2009. (Revised August 2010.)
- Article
Czech Mate: Expropriation and Investor Protection in a Converging World
By: Mihir A. Desai and Alberto Moel
This paper examines the expropriation of a foreign investor by a local partner and the subsequent resolution of that case through international arbitration in favor of the investor. Despite the investor's 99% interest in joint venture, the local partner managed to...
View Details
Keywords:
Joint Ventures;
Capital Markets;
Foreign Direct Investment;
Geographic Location;
Multinational Firms and Management;
Governance Controls;
Courts and Trials;
Rights;
Czech Republic;
United States
Desai, Mihir A., and Alberto Moel. "Czech Mate: Expropriation and Investor Protection in a Converging World." Review of Finance 12, no. 1 (2008): 221–251. (This paper is a revised version of ECGI Working Paper No. 62/2004.)
- February 2008
- Article
Does Focus Improve Operational Performance? Lessons from the Management of Clinical Trials
By: Robert S. Huckman and Darren Zinner
Huckman, Robert S., and Darren Zinner. "Does Focus Improve Operational Performance? Lessons from the Management of Clinical Trials." Strategic Management Journal 29, no. 2 (February 2008): 173–193.
- January 2006 (Revised July 2006)
- Case
Drug Testing in Nigeria (A)
By: Debora L. Spar
In 1996, a meningitis epidemic swept across Nigeria. Thousands of children were struck and, lacking appropriate medicine, were liable to die from the disease. Doctors at Pfizer had an antibiotic that could probably save most of these children's lives. The drug was new,...
View Details
Keywords:
Risk and Uncertainty;
Health Pandemics;
Health Testing and Trials;
Developing Countries and Economies;
Pharmaceutical Industry;
Nigeria
Spar, Debora L., and Adam Day. "Drug Testing in Nigeria (A)." Harvard Business School Case 706-033, January 2006. (Revised July 2006.)
- August 2005 (Revised December 2006)
- Case
Procter & Gamble: Electronic Data Capture and Clinical Trial Management
By: Robert S. Huckman and Mark J. Cotteleer
Considers whether the management of Procter & Gamble (P&G) Pharmaceuticals should adopt Web-based electronic data capture (EDC) as the default standard for the management of its clinical drug trials. Provides a detailed description of the existing paper-based process...
View Details
Keywords:
Health Testing and Trials;
Internet and the Web;
Information Technology;
Adoption;
Business Processes;
Industry Structures;
Technological Innovation;
Service Operations;
Pharmaceutical Industry;
United States
Huckman, Robert S., and Mark J. Cotteleer. "Procter & Gamble: Electronic Data Capture and Clinical Trial Management." Harvard Business School Case 606-033, August 2005. (Revised December 2006.)
- 2005
- Working Paper
Does Focus Improve Operational Performance? Lessons from the Management of Clinical Trials
By: Robert S. Huckman and Darren E. Zinner
Huckman, Robert S., and Darren E. Zinner. "Does Focus Improve Operational Performance? Lessons from the Management of Clinical Trials." Harvard Business School Working Paper, No. 05-073, May 2005.
- November 2003 (Revised September 2008)
- Case
Circle Gastroenterology Products (A)
By: Regina E. Herzlinger and James Weber
A new, minimally invasive medical device has achieved only one-third of its budget. Was the problem one of marketing strategy, sales, reimbursement, and/or clinical trials?
View Details
Keywords:
Health Testing and Trials;
Marketing Strategy;
Product Marketing;
Sales;
Medical Devices and Supplies Industry
Herzlinger, Regina E., and James Weber. "Circle Gastroenterology Products (A)." Harvard Business School Case 304-052, November 2003. (Revised September 2008.)
- August 2003 (Revised July 2023)
- Case
Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment
By: Regina E. Herzlinger and John McDonough
What can Dr. Dean Ornish learn from the successes and failures of his competitors in ameliorating morbid obesity to create a business model that will “do good” by combatting obesity and associated chronic diseases and “do well” by growing a widely adopted business?...
View Details
Keywords:
Three Pillars;
Industry Analysis;
Health Disorders;
Health Care and Treatment;
Innovation and Invention;
Business Model;
Analysis;
Innovation and Management;
Medical Specialties;
Mission and Purpose;
Health Industry
Herzlinger, Regina E., and John McDonough. "Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment." Harvard Business School Case 304-009, August 2003. (Revised July 2023.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the...
View Details
Keywords:
Decision Making;
Health Testing and Trials;
Innovation and Invention;
Markets;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research;
Research and Development;
Complexity;
Biotechnology Industry;
Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- February 2000 (Revised October 2000)
- Case
Kendle International Inc.
By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs
Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and...
View Details
Keywords:
Acquisition;
Financing and Loans;
Venture Capital;
Stock Options;
Banks and Banking;
Debt Securities;
International Finance;
Financial Strategy;
Management Skills;
Private Ownership;
Initial Public Offering;
Biotechnology Industry;
Pharmaceutical Industry
Crane, Dwight B., Paul W. Marshall, and Indra Reinbergs. "Kendle International Inc." Harvard Business School Case 200-033, February 2000. (Revised October 2000.)
- November 1994 (Revised December 1995)
- Case
Scripps Research Institute, The: November 1993 (Abridged)
By: Josh Lerner
In November 1993, Dr. Richard Lerner, president of the Scripps Research Institute, faces the challenge of maintaining his organization's financial and scientific vitality. A proposed cooperative venture with Sandoz has attracted considerable criticism. Meanwhile, a new...
View Details
Keywords:
Joint Ventures;
Financing and Loans;
Policy;
Management;
Organizational Change and Adaptation;
Problems and Challenges;
Research;
Nonprofit Organizations
Lerner, Josh. "Scripps Research Institute, The: November 1993 (Abridged)." Harvard Business School Case 295-068, November 1994. (Revised December 1995.)
- November 1991 (Revised April 1994)
- Case
Nucleon, Inc.
By: Gary P. Pisano
Nucleon is a small biotechnology company whose first potential product is about to enter clinical testing. Before Nucleon can begin clinical trials, however, its management must decide how and where to manufacture the product. Three options are being contemplated: 1)...
View Details
Keywords:
Factories, Labs, and Plants;
Entrepreneurship;
Health Testing and Trials;
Rights;
Product Development;
Production;
Partners and Partnerships;
Research and Development;
Biotechnology Industry
Pisano, Gary P. "Nucleon, Inc." Harvard Business School Case 692-041, November 1991. (Revised April 1994.)